0002001011-25-000046.txt : 20250610 0002001011-25-000046.hdr.sgml : 20250610 20250610193941 ACCESSION NUMBER: 0002001011-25-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250606 FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gray Nancy Ryan CENTRAL INDEX KEY: 0001714949 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 251038532 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INCORPORATED STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2025-06-06 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001714949 Gray Nancy Ryan 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 1 0 0 0 0 Common Stock 2025-06-06 4 A 0 1209 0.0 A 8094 D Non-Qualified Stock Option (right to buy) 105.99 2025-06-06 4 A 0 5783 0.0 A 2035-06-06 Common Stock 5783 5783 D Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray 2025-06-10